Study of Intravitreal REGN2176-3 in Participants With Neovascular ("Wet") Age-Related Macular Degeneration (AMD)

NCT02418754 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

505

Enrollment

INDUSTRY

Sponsor class

Stopped No additional efficacy seen with REGN2176-3 over aflibercept alone

Conditions

Neovascular Age-Related Macular Degeneration

Interventions

DRUG: REGN2176-3
DRUG: Intravitreal Aflibercept Injection (IAI)

Sponsor

Regeneron Pharmaceuticals